Dana Wallace, MS

Associate Director for Administration, Comprehensive Cancer Center

Departments

Comprehensive Cancer Center

Education

BS – Murray State University (1988)
MS – University of Memphis (1992)

Professional Experience

Ms. Wallace joined St. Jude in 1993. She has served as Project Leader Senior Biostatistician for the Department of Biostatistics as well as the Assistant Director of the Operations and Biostatistics Center for the NCI-funded Pediatric Brain Tumor Consortium (PBTC) prior to joining Cancer Center Administration. Ms. Wallace has significant experience collaborating with clinicians and scientists on clinical trial design, analysis, and operations. As Assistant Director, she coordinated the administrative activities of the PBTC Operations and Biostatistics Centers.

Contact Information

Dana Wallace, MS Cancer Center Administration MS 281, Room C7045A St. Jude Children’s Research Hospital 262 Danny Thomas Place Memphis, TN 38105-3678

Email: dana.wallace@stjude.org
Phone: (901) 595-2617
Fax: (901) 595-8600

Selected Publications

Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, Macdonald T, Jakacki R, Boyett JM, Kun LE. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium Study PBTC-018. J Clin Oncol 29(3):324-329, 2011. PMCID: PMC3056466 PUBMEDID: 21149652

Onar A, Ramamurthy U, Wallace D, Boyett JM. An operational perspective of challenging statistical dogma while establishing a modern, secure distributed data management and imaging transport system: the Pediatric Brain Tumor Consortium phase I experience. Clin Transl Sci 2(2):143-149, 2009. PMCID: PMC2877373 PUBMEDID: 20443880 NIHMSID: NIHMS201839.

Finlay JL, Dhall G, Boyett JM, Dunkel IJ, Gardner SL, Goldman S, Yates AJ, Rosenblum MK, Stanley P, Zimmerman RA, Wallace D, Pollack IF, Packer RJ; Children's Cancer Group. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. Pediatr Blood Cancer 51(6):806-11, 2008. PMCID: PMC2844080 PUBMEDID: 18802947

Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, Gronewold L, Stewart CF,Wallace D, Broniscer A, Hale GA, Kasow KA, Merchant TE, Morris B, Krasin M, Kun LE, Boyett JM, Gajjar A. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 26(22):3749-3755, 2008. PMCID: PMC2504739 PUBMEDID: 18669462 NIHMSID: NIHMSID48606.

Laughton SJ, Merchant TE, Sklar CA, Kun LE, Fouladi M, Broniscer A, Morris EB, Sanders RP, Krasin MJ, Shelso J, Xiong Z, Wallace D, Gajjar A. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 Trial. J Clin Oncol 26 (7):1112-1118, 2008. PUBMEDID: 18309946

Razzouk BI, Rose SR, Hongeng S, Wallace D, Smeltzer MP, Zacher M, Pui C-H, Hudson MM. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol25(10):1183-1189, 2007. PUBMEDID: 17401007

Broniscer A, Gururangan S, MacDonald TJ, Goldman S, Packer RJ,Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY, Kun LE, Boyett JM, Gajjar A, for the Pediatric Brain Tumor Consortium. Phase I trial of single-dose temozolomide and continuous administration of O⁶-benzylguanine in children with brain tumors: a Pediatric Brain Tumor Consortium Report. Clin Cancer Res 13(22):6712-6718, 2007. PUBMEDID: 18006772

Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813-820, 2006. PUBMEDID: 17012043

Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, Krull K, Chintagumpala M, Stargatt R, Ashley DM, Tyc VL, Kun L, Boyett J, and Gajjar A. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 23(24):5511-5519, 2005. PUBMEDID: 16110011

Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ. Clinical, histopathological and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol22(6):984-993, 2004. PUBMEDID: 14970185

Packer RJ, Boyett JM, Janss AJ, Stavrou T, Kun L, Wisoff J, Russo C, Geyer R, Phillips P, Kieran M, Greenberg M, Goldman S, Hyder D, Heideman R, Jones-Wallace D, August GP, Smith SH, Moshang T. Growth hormone replacement therapy in children with medulloblastoma: Use and effect on tumor control. J Clin Oncol 19(2):480-487, 2001. PUBMEDID: 11208842

Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A children’s cancer group study. J Clin Oncol 19(15):3470-3476, 2001. PUBMEDID: 11481352

Gilbertson R, Wickramasinghe C, Hernan R, Balaji V, Hunt D, Jones-Wallace D, Crolla J, Perry R, Lunec J, Pearson A, Ellison D. Clinical and molecular stratification of disease risk in childhood medulloblastoma. Br J Cancer 85(5):705-712, 2001. PMCID: PMC2364121 PUBMEDID: 11531256

Kaste SC, Hudson MM, Jones DJ, Fryrear R, Greenwald CA, Fleming ID, Pratt CB. Breast masses in women treated for childhood cancer: Incidence and screening guidelines. Cancer 82(4):784-792, 1998. PMID: 9477113

Hudson MM, Jones D, Boyett J, Sharp GB, Pui CH. Late mortality of long-term survivors of childhood cancer. J Clin Oncol 15(6):2205-2213, 1997. PMID: 9196132